ETFChannel.com
GILD Description — Gilead Sciences Inc

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

Company Name: 
Gilead Sciences Inc
Website: 
www.gilead.com
Sector: 
Biotechnology
Number of ETFs Holding GILD: 
138
Total Market Value Held by ETFs: 
$12,413,247,701.01
Total Market Capitalization: 
$87,895,000,000
% of Market Cap. Held by ETFs: 
14.12%
 ETF   GILD Weight   GILD Amount 
 VTI   0.18%   $2,498,761,170         
 VOO   0.22%   $1,866,641,672         
 QQQ   0.57%   $1,187,467,843         
 SPY   0.22%   $934,887,723         
 IVV   0.22%   $720,920,685         
 VTV   0.49%   $669,970,302         
 XLV   1.74%   $568,117,750         
 USMV   1.38%   $403,907,418         
 VYM   0.64%   $330,787,507         
 DVY   1.45%   $277,442,014         
List of all 138 ETFs holding GILD »
Quotes delayed 20 minutes

Email EnvelopeFree GILD Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.14 out of 4)
27th percentile
(ranked lower than approx. 73% of all stocks covered)

Analysts Forecast:
GILD Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding GILD | Gilead Sciences Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.